Kouroumalis Elias, Samonakis Demetrius, Voumvouraki Argyro
Department of Gastroenterology, University Hospital and Medical School, University of Crete, Heraklion, Crete, Greece.
Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece.
Hepat Med. 2018 Jun 18;10:43-53. doi: 10.2147/HMER.S135337. eCollection 2018.
Primary biliary cholangitis (PBC) is a chronic progressive cholestatic disease characterized by destruction of small- and medium-sized intrahepatic bile ducts. It is no longer a rare disease, since many new asymptomatic cases are incidentally identified. Liver biopsy is diagnostically critical but not always feasible or practical to be performed. Many potential, noninvasive, markers have been proposed to replace liver biopsy and further provide the assessment of disease severity and ultimate prognosis. In this review, we evaluated serum biomarkers proposed for diagnosis, extent of fibrosis, disease prognosis and attempts for early prediction of treatment response. Older biochemical and immunological markers are presented along with recent reports including the role of microRNAs and promising results based on proteomics and metabolomics.
原发性胆汁性胆管炎（PBC）是一种慢性进行性胆汁淤积性疾病，其特征是肝内中小胆管遭到破坏。由于许多新的无症状病例被偶然发现，它已不再是一种罕见疾病。肝活检在诊断上至关重要，但并非总是可行或实际可操作的。人们已经提出了许多潜在的非侵入性标志物来取代肝活检，并进一步评估疾病的严重程度和最终预后。在本综述中，我们评估了用于诊断、纤维化程度、疾病预后以及早期预测治疗反应的血清生物标志物。文中呈现了较老的生化和免疫标志物以及近期的报告，包括微小RNA的作用以及基于蛋白质组学和代谢组学的有前景的结果。
